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Abstract
Background: Invasive meningococcal disease (IMD), is a widely distributed, complex human disease affecting
all age categories. The causative agent, Neisseria meningitidis, is spread through aerosol respiratory droplets.
13 different serogroups have been identified, each with varying epidemiological features including prevalence,
virulence, immunogenicity, geographical and temporal distribution. Although preventative measures are available
for several of the serogroups, meningococcal disease caused by serogroup B is of particular interest due to the
challenge it presents concerning vaccine development.
Methods: A systematic review of peer reviewed studies and reports, the collection of data from national and
international health resources, along with the analysis of the Multi Locus Sequence Typing database was carried
out aimed at collecting information concerning serogroup B IMD and the epidemiology attached to it.
Results: A continuous output of related and novel STs occurring worldwide in terms of the hypervirulent clonal
complexes was observed both in published studies and the MLST database in this case using the eburst software,
which highlights the genetically diverse nature of serogroup B strains.
Conclusions: With the recent dominance of serogroup B IMD seen in many countries, along with the presence of
antibiotic resistance, vaccine development needs to target areas of the bacterium which tackle this widespread
and heterogeneous aspect of meningococcal meningitis disease.
Background
Invasive meningococcal disease (IMD) is a widely dis-
tributed, complex human disease affecting all age cate-
gories. As a naso-pharynx commensal bacterium,
Neisseria meningitidis is spread through aerosol respira-
tory droplets and under circumstances yet unclear, can
progress from a carriage state to IMD.
IMD and the economic burden associated with it is of
significant importance for public health, not only in the
epidemic prone regions, but also in areas with sporadic
and hyperendemic forms of the disease [1,2].
According to differences in the chemical composition
of the bacterial polysaccharide capsule, 13 different ser-
ogroups have been identified, each with varying epide-
miological features including prevalence, virulence,
immunogenicity, geographical and temporal distribution.
Meningococcal disease caused by serogroup B is of par-
ticular interest due to the challenge it presents
concerning vaccine development. Historically, serogroup
A, and to a lesser extent C, have been the main causes
of large epidemics as well as pandemics, mostly in
Africa, Asia and Southern America. Nevertheless, ser-
ogroup B has posed a more recent threat with sporadic,
endemic and epidemic occurrences being recorded in
North America, Europe, South America and Australasia
[3,4]. Since the introduction of vaccines against ser-
ogroups A and C, serogroup B has emerged as an
important cause of IMD in regions such as Europe,
Latin America and Northern America as seen in figure
1, especially due to the lack of preventative measures for
this serogroup. More specifically, reports of major ser-
ogroup B epidemics started to surface during the second
half of the 20
th century in Iceland and Norway (1976-
86) [5], Turkey [6] as well as Cuba (1976) [7]. These
epidemics were followed by outbreaks in Chile 1983-
1987 [8], Brazil [9], the Netherlands [10], Belgium [11]
along with New Zealand in the 1990s [12].
Since the 1990s, localized outbreaks have been
reported in Oregon, USA where a hyperendemic
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persisted albeit with a decreased incidence until the
present day [13]. In the Seine-Maritime department,
France [14] a hyperendemic situation has also been
reported since 2003 attributed to the serogroup B
ST32 (ET 5) complex also dominating in Oregon. In
addition to the increasing importance of serogroup B
in Europe and Northern America which has been ris-
ing steadily in the past decade [3,4], recent studies in
Asia have also reported this serogroup as the dominant
o n ea ss e e ni nT a i w a na n dJ a p a n[ 1 5 , 1 6 ] .F o rt h ea n a -
lysis of serogroup B data, understanding the currently
used molecular typing methods is essential. Data
obtained from the MLST database as described in the
Figure 1 Incidence of Meningococcal Disease by serogroup. Distribution of meningococcal meningitis serogroups in the different regions
present throughout 1994-2007. Colours correspond to the mentioned serogroups. Incidence given per 100,000 population.
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study http://www.mlst.net [17].
Evolutionary developments can be analysed using this
method in combination with the e-BURST (Based Upon
Related Sequence Types) application as described below.
MLST is based on strain characterization by sequencing
internal fragments of seven housekeeping genes: abcZ
(putative ABC transporter) adk (adenylate kinase), aroE
(shikimate dehydrogenase), fumC (fumarate hydratase),
gdh (glucose-6-phosphate dehydrogenase), pdhC (pyru-
vate dehydrogenase subunit) and pgm (phosphogluco-
mutase). These genes are coding proteins required in
the upkeep of the bacteria, and are constantly expressed
[18].
Horizontal gene transfer is a common occurrence in
the Neisseria genus [19], which creates a highly diverse
gene pool, and large numbers of genetically heteroge-
neous strains are constantly created within serogroup B
Neisseria meningitidis [20], especially at the outer mem-
brane protein level whereby a variety of combinations
are present. Epidemics are often due to a select number
of hypervirulent clonal complexes [21], which are
defined as closely related groups of isolates in which all
sequence types (STs) are linked to at least one other
single locus variant (SLV) also belonging to the clonal
complex. In general, STs can be grouped into three
categories: global, related and novel sequence types.
This study concentrates on analysing the distribution
and heterogeneity of hypervirulent complex B
meningococci causing IMD through the analysis of
available epidemiological and MLST data on a localized
as well as worldwide scale.
Methods
A systematic review aimed at identifying reports, studies
and data concerning serogroup B IMD and the epide-
miology attached to it was carried out. International,
national and regional websites were consulted for data.
Search terms included meningococcal meningitis, Neis-
seria meningitidis, country names, serogroup ACWY and
B epidemiology, accessed through Pubmed http://www.
ncbi.nlm.nih.gov/pubmed/, as well as government public
health and statistics sites for individual countries and
regional databases. Exclusion criteria for data was imple-
mented when figures for total case numbers provided
were not clear concerning the inclusion of all bacterial
meningitis (for example Streptococcus pneumoniae and
Haemophilus influenzae type B) versus meningococcal
meningitis (caused by Neisseria meningitidis) alone. Data
from this review were used for figures 1, 2 and in table 1.
The MLST website [22] was searched for invasive ser-
ogroup B data by including the search terms for the
desired clonal complexes (ST 41/44, 32, 11, 8 and 269),
country (all countries where data was available), species
(Neisseria meningitidis), serogroup (serogroup B), dis-
ease (meningococcal meningitis), epidemiology, age and
year, whilst excluding the search terms: carriage, other
species and other serogroups (A, C, W135, Y, other and
ST-41/44 complex
ST-32 complex
unknown
ST-18 complex
ST-269 complex
ST-35 complex
ST-8 complex
ST-11 complex
Figure 2 Distribution of most common ST complexes for serogroup B IMD. Prevalence of the main serogroup B meningococcal disease
clonal complexes found in the MLST database, accessed July 2009.
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cific fields: clonal complexes (STs 41/44, 32, 11, 8 and
269) and entered into the program eBurst V3 http://
eburst.mlst.net/[23] in order identify mutually exclusive
groups of related genotypes in the population, as well as
identifying the founding ST of each group, including the
effect of collection years (pre 1990s and post 1999).
Data from the MLST analysis were used for figures 3, 4,
5, 6, 7 &8.
The final traditional hypervirulent clonal complex of
serogroup B is the ST 8 cc (Figure 6), which is also dis-
tributed on a global scale. The STs 8, 153 and 335 are
the most common STs in this group.
Further hypervirulent clonal complexes associated
with the B capsule have emerged, this include the
ST209 cc found in Canada, specifically strain B:17:P1.19
[25]. Interestingly, a comparison of strains belonging to
the ST269 cc during the 1990s or after 1999 (Figure 7
&8) in the United Kingdom showed that although the
main STs were present in both time frames, the number
of different STs was higher among the strains isolated
post 1999, as was the percentage of antibiotic resistant
strains (penicillin, sulphonamide, ceftriaxone, chloram-
phenicol, cefotaxime, rifampicin and ciprofloxacin ).
Results
The most common ST complexes for serogroup B inva-
sive meningococcal disease found when analyzing the
distribution and the frequency of the STs recorded in
the MLST database, accessed in July 2009, are seen in
(Figure 2). Note that not all countries report their infor-
mation to the MLST database, and although evidence
suggests that the prevalence of complexes shown in
figure 2 are in correct hierarchy, not all STs are sent
and therefore analysed in the MLST database.
Hypervirulent clonal complexes exist for all ser-
ogroups responsible for IMD, with the ST 41/44, 32, 11
and 8 also known as lineage III, ET-5, ET 37 and the
A4 cluster respectively, being responsible for the major-
ity of IMD in serogroup B [24]. Another emerging
hypervirulent clonal complex, ST 269, well documented
in Law et al., 2006 [25], is also represented in (Figure 2).
Figures 3, 4, 5, 6, 7 &8 show the founding genotype of
each clonal complex and the relationship between the
main cluster and the different strains according to the
distance shown by the connecting lines. Each dot repre-
sents an ST, whereby STs present at one dot distance
symbolize a Single Locus Variant (SLV), and the dots
located at two distances are the Double Locus Variants
(DLV). Where further larger clusters are present, this
would indicate that a primary founder has diversified
and produced its own SLVs as described in http://
eburst.mlst.net/v3/instructions/3.asp.
The ST41/44 complex (Figure 3), with over 1000
documented STs is the most diverse clonal complex
associated with serogroup B meningococcal disease. STs
40, 41, 42, 43, 44, 45, 146, 154, 170, 303, 437, 1403 and
3346 are the most widespread STs on a geographical
level (data not shown). Importantly, it was responsible
for a large epidemic in New Zealand caused by strain
type B:4:P1.7-2,4 [21]. Highlighted in (Figure 3), the
most common STs in the ST41/44 complex were 41 fol-
lowed by 44, 42, 40 and 154. This common complex has
caused epidemics in The Netherlands and New Zealand,
and has also been the dominant cause of IMD in Ire-
land, Belgium, and Italy [3,26].
Table 1 STs of meningococci which have recently emerged
Country Japan Korea China Brazil
Related to widespread clonal complexes ST 44 to ST 2055
ST 23 to ST 2038
ST 32 to ST 2145
ST 41/44 to ST 6667 ST 44 to ST 5635
ST 230 to ST 5626
ST 658 to ST 5644
ST 32 to:
ST 639
ST 3764
ST 3765
ST 3768
ST 3779
ST 3773
ST 3774
ST 3778
ST 3776
ST 3769
ST 3775
ST 35 to ST 3771
ST 269 to ST 3772
Novel clonal complexes ST 2046
ST 2149
ST 2032
ST 5666
ST 5615
ST 4821
ST 3766
ST 3767
ST 3777
ST 3779
ST 3780
ST 3781
ST 3782
List of novel and related to widespread clonal complexes STs in selected countries
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Page 4 of 9Figure 3 eBurst representation of IMD clonal complex 41/44. Each dot represents a ST. Distance from each ST to the founding ST located in
the middle of a cluster, indicates diversity level. Dot distance shows difference in single locus variants. Only major STs are labelled.
Figure 4 eBurst representation of IMD clonal complex 32.
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Figure 6 eBurst representation of IMD clonal complex 8.
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Figure 8 eBurst representation of IMD clonal complex 269, post 1990’s.
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several large outbreaks in Iceland, Norway, France
Denmark, the Netherlands, United Kingdom [27-30]. It is
also spreading to Central and Southern American regions
affecting Cuba, Chile and Brazil [7,31,8]. As mentioned
above, it is also the ST clonal complex responsible for
the hyperendemic situation in the Seine Maritime depart-
ment in France, caused by the phenotype B:14:P1-7,16 as
well as in Oregon, USA where the phenotype B:15:
P1.7,16 has caused the majority of IMD in the region. In
this clonal complex, the most wide spread strains belong
to STs 32, 33, 34, 259, 265, 343, 463 and 749.
The ST 11 clonal complex (Figure 5), although usually
associated with serogroup C, and in the Mecca out-
breaks with W135 [32-34] also comprises a diversity of
STs. In this complex, the number of different ST is
comparatively low with the main ST being ST 11.
When comparing the global ST distribution with
local datasets such as those found in Taiwan [14], Bra-
zil [35], France [13] and the United Kingdom, similar
e-burst structures were observed in general, yet on a
local scale, the main difference was seen in the amount
of clusters and STs present as well as their diversifica-
tion patterns. In general there was an increase in num-
ber of different STs seen with passing time. As shown
in (Figure 7 &8), related or novel STs for serogroup B
arise regularly during time, as reported in China [36],
Korea [37], Japan [15], New Zealand [21] and Brazil
[35] as seen in Table 1.
This well documented process brings to attention the
highly genetically diverse nature of serogroup B strains
[20]. Several hypotheses have arisen including the effects
of carriage processes [21], vaccine replacement [25] or
the presence of new allelic recombinations [38]. In this
light, vaccine development efforts need to be tailored to
this phenomenon.
Discussion
As a bacterium of a highly recombining nature, allowing
for a vast genetic variability [39], and the emergence of
hypervirulent strains, challenges have remained persis-
tent in the development of effective prevention and con-
trol methods for this disease. As seen in Table 1, there
is a continued output of related and novel STs occurring
worldwide. There are several main hypervirulent strains
as seen in (Figure 2), due to the commensal nature of
N. meningitidis, and as seen in figure 3, 4, 5, 6, 7 &8
and documented in many studies, the development of
new strains is likely to continue. Perhaps by studying
the patterns of ST distribution, the identification and
targeting of several STs for vaccine purposes could be
achieved, and highlight the fact that local vaccines
would not be a long term solution.
Still a poorly understood aspect of meningococcal dis-
ease is the role of carriage versus invasive disease. As
described in [40], even within clonal complexes, differ-
ences in carriage versus invasive disease causing groups
exist. For example as seen in cases involving the Czech
Republic, Greece, and Norway, three main STs in ser-
ogroup B have been associated with invasive disease:
ST32, ST 269 and ST18, whilst ST 35 was distinctively
more linked to carriage isolates[41]. Additionally, it has
been shown that carriage isolates seem to be more
diverse than invasive ones [36].
Even if an effective vaccine was developed targeting
the major antigens in serogroup B invasive disease caus-
ing STs, there have been reports of capsule replacement
as seen in Italy [42] from serogroup C to serogroup B
(ST11). Capsule switching has also been reported in two
distinct scenarios, firstly during an epidemic as seen in
the Czech Republic [43] with the majority of replace-
ment being from C:2a:P1.2,5. to B:2a:P1.2(P1.5), or after
an immunization campaign as described in Canada
whereby serogroup B ST-269, B:17:P1.19 emerged from
C:2a:P1.5,2 after a vaccine against serogroup C disease
was distributed [25].
Conclusions
Any potential vaccine against serogroup B disease would
need to target areas of the agent which are not linked
by serogroup alone but more specifically to characteris-
tics affecting the bacterium itself as targeted by a gen-
eral protein based vaccine. Additionally, the pressure of
serogroup B dominance seen in many countries at pre-
sent combined with the presence of antibiotic resistance,
vaccine development needs to target areas of the bacter-
ium which tackle this widespread and heterogeneous
aspect of meningococcal meningitis disease.
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